Andrx, Genpharm Inc. generics news

The companies ended a dispute regarding the timing of their respective filings with the FDA for generic versions of AstraZeneca plc's Prilosec omeprazole to treat duodenal/gastric ulcers and gastro-esophageal reflux disease. ADRX will market the first product approved and the companies will share royalties through cross-licenses. Genpharm, a subsidiary of Merck KGaA (Darmstadt, Germany), will initially receive 15 percent of profits. If three or more generic versions of Prilosec are approved, Genpharm's share will drop to 10 percent for four years, after which the royalty will end. ...